- Home
- VIST vs DNTH Comparison
VIST vs DNTH Comparison
Compare VIST & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIST | DNTH |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VIST | DNTH |
|---|---|---|
| Price | $55.65 | $89.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 18 |
| Target Price | $93.85 | ★ $139.25 |
| AVG Volume (30 Days) | ★ 1.0M | 894.5K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $79.10 | $36.90 |
| Revenue Next Year | $3.50 | N/A |
| P/E Ratio | $7.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.71 | $34.29 |
| 52 Week High | $81.44 | $117.88 |
Technical Indicators
Market Signals| Indicator | VIST | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 26.61 | 60.24 |
| Support Level | $53.80 | $89.21 |
| Resistance Level | $59.20 | $91.36 |
| Average True Range (ATR) | 2.79 | 4.21 |
| MACD | -1.52 | 1.63 |
| Stochastic Oscillator | 9.00 | 85.17 |
Price Performance
Historical ComparisonAbout VIST Vista Energy S.A.B. de C.V. each representing one series A share with no par value
Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, it operates in Argentina and Mexico. Product-wise, the firm generates the majority of its revenue from crude oil sales, natural gas sales, and LPG sales.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.